Where does Inserm rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Inserm ranks #11,290 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Inserm hold?

Inserm holds 27 US utility patents granted between 2015 and 2024, spanning 23 technology areas.

What is Inserm's Innovation Score?

Inserm has an Innovation Score of 49.8 out of 100 (top 14% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Inserm focus on?

Inserm's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 17 patents, ranking #1,155 of 6,058 assignees active in that subclass. Grants appear in 23 CPC subclasses total.

Is Inserm's patent grant rate increasing or decreasing?

Inserm's recent grant velocity is +45% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Inserm's patents?

Inserm's patents average 11.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Inserm patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Inserm

USPTO PatentsView assignee record - 27 granted patents across 23 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Inserm ranks #11,290 of 49,997 tracked US assignees by granted-patent volume, with 27 patents across 23 technology areas.

#11,290
of 49,997 US assignees by volume: Top 14%
by Innovation Score (49.8/100): 11.5
avg claims per patent: +45%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11290 · Foreign Corporation #11,290 · 27 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 27 grants
UPPER-Q #11,290/49,997
PHOTO-FINISH Imax
CPC-FOCUS A61P · 23 areas
INNOV-PAR 49.8/100
CLAIMS-PAR 11.5 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +45% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Imax Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Inserm’s 49.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.5 pts (23%) Velocity 14.4 pts (29%) Breadth 17.0 pts (34%) Claim depth 6.9 pts (14%)

Qualcomm Incorporated · highest

85
Inserm · this assignee

50
Intex Marketing · near

50
MAS Innovation… · near

50
Utica Leaseco · near

50
Sakata Seed America · near

50
3D Lighting… · lowest

7

What this shows Inserm's Innovation Score is 49.8/100 (top 14% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Inserm?

Each dot is one of Inserm’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Inserm’s own 11.5 claims/patent is at or below the 18.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Inserm vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Inserm's grants concentrate

Inserm is a focused PatentsView assignee: 23 CPC subclasses with 63% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (9 grants) versus a trough of 1 in 2015. By volume, Inserm sits between Imax Corporation and IQE plc.

Inserm's three-year grant acceleration

Inserm shows 13 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Imax

27
Immervision

27
INA Acquisition

27
Infovision Optoel…

27
Intradin (Shangha…

27
Intrexon Actobiot…

27
Ipgoal Microelect…

27
IQE

27
Inserm ◀

27

What this shows Inserm holds 27 patents at rank #11,286, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Inserm

By rank, the assignees closest to #11,286 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Inserm's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Inserm, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Inserm ranks #1,155 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (50 here).

Utica Leaseco, LLC 50 MAS Innovation (Private) Limited 50 Intex Marketing Ltd. 50 Sakata Seed America, Inc. 50

Inserm's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

50 Top 14% higher than 86% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Inserm patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	3.7%
2016	1	3.7%
2018	6	22.2%
2019	3	11.1%
2020	1	3.7%
2021	2	7.4%
2022	9	33.3%
2023	3	11.1%
2024	1	3.7%

Which technologies does Inserm patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 17

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 16

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 9

C07K - Peptides 6

Y02A - Technologies FOR Adaptation TO Climate Change 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C12Y - Enzymes 3

C07D - Heterocyclic Compounds 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

A61B - DIAGNOSIS; SURGERY; Identification 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

C07C - Acyclic OR Carbocyclic Compounds 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

H04L - Transmission OF Digital Information, e.g. Telegraphic Communication 1

Top 15 of 23 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Inserm's patent record in context - here's where to go next.

Inserm's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 63% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #11,290 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Inserm against Imax Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 49.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.